Company Overview
BriaCell Therapeutics Corp., a pre-clinical stage immuno-oncology company, engages in developing targeted immunotherapies to transform cancer care. Its lead candidate is Bria-IMT, a targeted immunotherapy program against end-stage breast cancer that is in Phase 3 clinical trials. The company develops Bria-OTS, a personalized off-the-shelf immunotherapy; and a soluble CD80 protein therapeutic that acts as a stimulator of the immune system and an immune checkpoint inhibitor. It has a license agreement with the University of Maryland, Baltimore County to develop and commercialize soluble CD80 as a biologic agent for the treatment of cancer. BriaCell Therapeutics Corp., has a collaboration with MSK Accelerator to accelerate the clinical development of Bria-OTS+ for multiple cancer indications including metastatic breast cancer, prostate cancer, and other cancers. The company is headquartered in West Vancouver, Canada.
Growth & Price Performance
Stock Price Performance
| 1 Year: | -50.35% |
| 6 Months: | -4.92% |
| 3 Months: | +15.70% |
| 1 Month: | -1.79% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)48.86 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
No notable strengths flagged.
CONS
- Trading 74.1% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | BCTX BriaCell Therapeutics Corp. PHARMA | 3.58 | -4.26 | $31.15M | 0.00% | - | - | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Oct 2021 | Jan 2022 | Apr 2022 | Oct 2022 | Jan 2023 | Apr 2023 | Oct 2023 | Jan 2024 | Apr 2024 | Oct 2024 | Jan 2025 | Apr 2025 | Oct 2025 | Jan 2026 | Apr 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Income | -2.28M | -3.65M | -4.12M | -5.40M | -4.49M | -5.68M | -8.50M | -9.83M | -9.23M | -5.15M | -7.17M | -6.33M | -8.32M | -7.53M | -7.62M |
| Net Income | -27.53M | 11.16M | -10.02M | -1.11M | -11.88M | -4.90M | 6.00M | -11.29M | 1.72M | -5.80M | -6.29M | -6.13M | -8.20M | -7.22M | -7.16M |
| Diluted EPS | - | 0.04 | -0.65 | -0.07 | -0.77 | -0.32 | -0.50 | -10.64 | 1.61 | -32.67 | -23.31 | -16.42 | -4.35 | -2.58 | -0.99 |
| R&D Expense | 875.64K | 1.71M | 2.27M | 3.26M | 3.05M | 3.86M | 6.86M | 8.26M | 7.66M | 3.67M | 5.68M | 4.81M | 6.68M | 6.05M | 5.97M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Jul 2021 | Jul 2022 | Jul 2023 | Jul 2024 | Jul 2025 |
|---|---|---|---|---|---|
| Operating Income | -6.98M | -15.29M | -23.27M | -33.33M | -27.20M |
| Net Income | -13.82M | -26.84M | -20.30M | -4.79M | -26.31M |
| Diluted EPS | - | -1.73 | -1.30 | -43.68 | -62.19 |
| R&D Expense | 2.02M | 8.02M | 15.34M | 27.18M | 21.27M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Jul 2020 | Jul 2021 | Jul 2022 | Jul 2023 | Jul 2024 | Jul 2025 |
|---|---|---|---|---|---|---|
| Total Assets | - | 58.04M | 42.58M | 27.16M | 5.87M | 21.65M |
| Total Equity | -2.74M | 27.67M | 10.33M | -3.78M | -2.68M | 17.33M |
| Cash & Equivalents | - | 57.27M | 41.04M | 21.25M | 862.09K | 10.49M |
| Current Liabilities | - | 556.79K | 941.09K | 1.80M | 7.46M | 3.98M |
Cash Flows (Annual)
Figures in USD.
| Metric | Jul 2021 | Jul 2022 | Jul 2023 | Jul 2024 | Jul 2025 |
|---|---|---|---|---|---|
| Operating Cash Flow | -7.75M | -12.48M | -23.74M | -24.13M | -28.17M |
| Investing Cash Flow | - | - | - | -681.80K | -7.65M |
| Financing Cash Flow | 65.00M | -3.74M | 3.95M | 4.42M | 45.45M |
| Capital Expenditure | - | - | - | -456.80K | - |
| Free Cash Flow | - | - | - | -24.58M | - |
Ratios (Annual)
Figures in %.
| Metric | Jul 2021 | Jul 2022 | Jul 2023 | Jul 2024 | Jul 2025 |
|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - |
| Net Margin % | - | - | - | - | - |
| ROE % | -49.9% | -259.8% | 537.5% | 178.5% | -151.8% |
| ROCE % | -12.1% | -36.7% | -91.8% | 2,097.7% | -153.9% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Cable Car Capital, LP | 2.49% | 216.82K | $912.82K |
| 2 | Sabby Management, LLC | 0.93% | 80.72K | $339.83K |
| 3 | Iridian Asset Management LLC | 0.75% | 65.00K | $273.65K |
| 4 | UBS Group AG | 0.50% | 43.64K | $183.73K |
| 5 | HRT Financial LP | 0.40% | 34.90K | $146.94K |
| 6 | Jane Street Group, LLC | 0.30% | 26.52K | $111.63K |
| 7 | Luminarx Capital Management LP | 0.17% | 15.00K | $63.15K |
| 8 | National Bank of Canada/FI/ | 0.02% | 1.80K | $7.59K |
| 9 | Morgan Stanley | 0.01% | 1.03K | $4.35K |
| 10 | Federation Des Caisses Desjardins Du Quebec | 0.01% | 450 | $1.89K |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for BCTX
Nature Medicine features a BriaCell trial among 11 shaping medicine in 2026 - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivgFBVV95cUxQdFFXbzZ5NFpZTktMT0c0aDhUTm4xdjBJN0ZBQUxETUw4VmpiWDhJb0RFekJJUE9qMG1JUmNZcGpjdV9JUzhoczNPWkpaR1ZLaS05TWowSVkzTUN6R3hSRmlmNjZLQzRIQkpWX1FkLUhFaHJpMThES2RQMG9BNXhOR2dfQjhBZEwwMC1LZU…
BCTX Stock Pulls Back As Traders Gauge Biotech Risk - timothysykes.com
<a href="https://news.google.com/rss/articles/CBMihAFBVV95cUxPZENWUFl0SVV4UlJSMWJBZmVxbGk4NTZ6SmVkX3p2cnd2dHkzQ0Q2UlZDOURtU05xTUFaXy1KclNwNjEzdEdZR2RySTFRN0cwSWRDMzdMSkpvekRETTBhNHJ0NzktT01halNSQVU3a2F4RVc5bUlRSjFwN3N0RldTemhBbVU?oc=5" targ…
Why Did BCTX Stock Surge 50% Today? - Stocktwits
<a href="https://news.google.com/rss/articles/CBMingFBVV95cUxOTWtCMHVYWVgyMEFIWkVEYVlycEdZX0E2Z2JFNzljemNMMnZyQi05dE4zSHMyTk1FN3oxX3F0SGpwQ0Z1NjJaZkRVbEJ6alJkNHVMdE40bnU1ck9VVHR3b2FmNGhMLVNKbDRhajRjRW1uYXVEeGlEUko2N2dSamYyczZRUHBtZU51Vm1WVE…
BCTX - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE9IYS1sUS1vTzg0UjlkT0J6VFUySWtYRzlUblBaZ0dzRjZZb0xWbmY3eVVPRUhITkhSd0prX2E1MkJ5RmlTSEE?oc=5" target="_blank">BCTX</a> <font color="#6f6f6f">Finviz</font>…
Briacell Therapeutics Corp (BCTX) Key Financial Ratios – Valuation, Profitability & More - Value Research
<a href="https://news.google.com/rss/articles/CBMimAFBVV95cUxNdFBDRUVoTXNBRHdCOS1iWmxDN3dPSHVtUDhyZUdVQTJPU1RXVlJkYU1SRG1kdjc1WFpGQUY5NW1QTmRlYy1EUjVSSFhCOWQ2OVI2V3dzRXNTWkttc0t6VVBDMXRSX2laTzJLblhEaWZINVBmQkFzT2pJTmc4SHc3NzNEUnctYV9DVzlhNT…
Cancer biotech BriaCell raises $4.7M in share sale - Stock Titan
<a href="https://news.google.com/rss/articles/CBMinwFBVV95cUxOMlI1dWlmc3ZUamFtRVduX3hqZHZMazE5VUdPLUI5X1A0b0lvOUhxaEtKeHZqd2RPdlB5MUZxRlBlV1k1QVhOUzVaUEJPc0xNVTI1U251VllWNUx3LXN2QkdRVlFqdzJzUmQyek5TTkFVVmFVYzQ2VVhzZndCenBSQ2tQb3BXLXlVejNxNk…
BCTX — Frequently Asked Questions
What is the current share price of BriaCell Therapeutics Corp. (BCTX)?
As of 2026-09-19 21:16 PDT, BriaCell Therapeutics Corp. (BCTX) trades at $3.58 on NasdaqCM. Its 52-week range is $2.74 to $13.79.
What is the market capitalisation of BCTX?
BriaCell Therapeutics Corp. (BCTX) has a market capitalisation of $31.15M on NasdaqCM.
What is the P/E ratio of BCTX?
BCTX trades at a trailing price-to-earnings (P/E) ratio of -4.26. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is 1.09.
Is BCTX a good stock to buy?
This page provides a data-driven analysis of BriaCell Therapeutics Corp. (BCTX), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.